Emulsions of fats or lipids used primarily in parenteral feeding.
Colloids formed by the combination of two immiscible liquids such as oil and water. Lipid-in-water emulsions are usually liquid, like milk or lotion. Water-in-lipid emulsions tend to be creams. The formation of emulsions may be aided by amphiphatic molecules that surround one component of the system to form MICELLES.
SURFACE-ACTIVE AGENTS that induce a dispersion of undissolved material throughout a liquid.
Oil from soybean or soybean plant.
The administering of nutrients for assimilation and utilization by a patient who cannot maintain adequate nutrition by enteral feeding alone. Nutrients are administered by a route other than the alimentary canal (e.g., intravenously, subcutaneously).
The glyceryl esters of a fatty acid, or of a mixture of fatty acids. They are generally odorless, colorless, and tasteless if pure, but they may be flavored according to origin. Fats are insoluble in water, soluble in most organic solvents. They occur in animal and vegetable tissue and are generally obtained by boiling or by extraction under pressure. They are important in the diet (DIETARY FATS) as a source of energy. (Grant & Hackh's Chemical Dictionary, 5th ed)
The delivery of nutrients for assimilation and utilization by a patient whose sole source of nutrients is via solutions administered intravenously, subcutaneously, or by some other non-alimentary route. The basic components of TPN solutions are protein hydrolysates or free amino acid mixtures, monosaccharides, and electrolytes. Components are selected for their ability to reverse catabolism, promote anabolism, and build structural proteins.
Fats present in food, especially in animal products such as meat, meat products, butter, ghee. They are present in lower amounts in nuts, seeds, and avocados.
Unctuous combustible substances that are liquid or easily liquefiable on warming, and are soluble in ether but insoluble in water. Such substances, depending on their origin, are classified as animal, mineral, or vegetable oils. Depending on their behavior on heating, they are volatile or fixed. (Dorland, 28th ed)
Oils derived from plants or plant products.
Triglycerides are the most common type of fat in the body, stored in fat cells and used as energy; they are measured in blood tests to assess heart disease risk, with high levels often resulting from dietary habits, obesity, physical inactivity, smoking, and alcohol consumption.
FATTY ACIDS found in the plasma that are complexed with SERUM ALBUMIN for transport. These fatty acids are not in glycerol ester form.
A peptide, of about 33 amino acids, secreted by the upper INTESTINAL MUCOSA and also found in the central nervous system. It causes gallbladder contraction, release of pancreatic exocrine (or digestive) enzymes, and affects other gastrointestinal functions. Cholecystokinin may be the mediator of satiety.
The administration of liquid medication, nutrient, or other fluid through some other route than the alimentary canal, usually over minutes or hours, either by gravity flow or often by infusion pumping.
A generic term for fats and lipoids, the alcohol-ether-soluble constituents of protoplasm, which are insoluble in water. They comprise the fats, fatty oils, essential oils, waxes, phospholipids, glycolipids, sulfolipids, aminolipids, chromolipids (lipochromes), and fatty acids. (Grant & Hackh's Chemical Dictionary, 5th ed)
A trihydroxy sugar alcohol that is an intermediate in carbohydrate and lipid metabolism. It is used as a solvent, emollient, pharmaceutical agent, and sweetening agent.
A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement.
(Z)-9-Octadecenoic acid 1,2,3-propanetriyl ester.
A nutritional reservoir of fatty tissue found mainly in insects and amphibians.
An infant during the first month after birth.
Liquid perfluorinated carbon compounds which may or may not contain a hetero atom such as nitrogen, oxygen or sulfur, but do not contain another halogen or hydrogen atom. This concept includes fluorocarbon emulsions and fluorocarbon blood substitutes.
Fatty tissue inside the ABDOMINAL CAVITY, including visceral fat and retroperitoneal fat. It is the most metabolically active fat in the body and easily accessible for LIPOLYSIS. Increased visceral fat is associated with metabolic complications of OBESITY.
Fatty tissue under the SKIN through out the body.
Deposits of ADIPOSE TISSUE throughout the body. The pattern of fat deposits in the body regions is an indicator of health status. Excess ABDOMINAL FAT increases health risks more than excess fat around the hips or thighs, therefore, WAIST-HIP RATIO is often used to determine health risks.
Fatty tissue in the region of the ABDOMEN. It includes the ABDOMINAL SUBCUTANEOUS FAT and the INTRA-ABDOMINAL FAT.
Specialized connective tissue composed of fat cells (ADIPOCYTES). It is the site of stored FATS, usually in the form of TRIGLYCERIDES. In mammals, there are two types of adipose tissue, the WHITE FAT and the BROWN FAT. Their relative distributions vary in different species with most adipose tissue being white.
Sorbitan mono-9-octadecanoate poly(oxy-1,2-ethanediyl) derivatives; complex mixtures of polyoxyethylene ethers used as emulsifiers or dispersing agents in pharmaceuticals.
Blocking of a blood vessel by fat deposits in the circulation. It is often seen after fractures of large bones or after administration of CORTICOSTEROIDS.
Relating to the size of solids.
A mixture of liquid hydrocarbons obtained from petroleum. It is used as laxative, lubricant, ointment base, and emollient.

Delay of preterm delivery in sheep by omega-3 long-chain polyunsaturates. (1/477)

A positive correlation has been shown between dietary intake of long-chain omega-3 fatty acids in late pregnancy and gestation length in pregnant women and experimental animals. To determine whether omega-3 fatty acids have an effect on preterm labor in sheep, a fish oil concentrate emulsion was continuously infused to six pregnant ewes from 124 days gestational age. At 125 days, betamethasone was administered to the fetus to produce preterm labor. Both the onset of labor and the time of delivery were delayed by the fish oil emulsion. Two of the omega-3-infused ewes reverted from contractions to nonlabor, an effect never previously observed for experimental glucocorticoid-induced preterm labor in sheep. Maternal plasma estradiol and maternal and fetal prostaglandin E2 rose in control ewes but not in those infused with omega-3 fatty acid. The ability of omega-3 fatty acids to delay premature delivery in sheep indicates their possible use as tocolytics in humans. Premature labor is the major cause of neonatal death and long-term disability, and these studies present information that may lead to a novel therapeutic regimen for the prevention of preterm delivery in human pregnancy.  (+info)

Prolonged elevation of plasma free fatty acids desensitizes the insulin secretory response to glucose in vivo in rats. (2/477)

Prolonged exposure of pancreatic islets to free fatty acids (FFAs) inhibits glucose-stimulated insulin secretion (GSIS) in vitro. However, FFA inhibition of GSIS has not been clearly demonstrated in vivo. We examined the in vivo effect of prolonged elevation of plasma FFAs on GSIS using a two-step hyperglycemic clamp in rats treated with a 48-h intravenous infusion of either 20% Intralipid plus heparin (INT) (5 microl/min plus heparin, 0.1 U/min; n = 8), oleate (OLE) (1.3 microEq/min; n = 6), saline (SAL) (n = 6), or bovine serum albumin (BSA) (vehicle for OLE; n = 5). Because there was no difference in any of the parameters between BSA and SAL rats, these groups were combined as control rats (CONT) (n = 11). At the end of the 48-h OLE/INT/CONT infusions, after an overnight fast, plasma glucose was clamped for 2 h at 13 mmol/l and for another 2 h at 22 mmol/l. Preclamp plasma FFAs were elevated twofold (P < 0.01) versus CONT with both INT and OLE (NS, INT vs. OLE). Preclamp glucose, insulin, and C-peptide levels were higher in INT than in CONT rats (P < 0.05), suggesting insulin resistance, but they were not different in OLE and CONT rats. The insulin and C-peptide responses to the rise in plasma glucose from basal to 13 mmol/l were lower in OLE (336 +/- 72 pmol/l and 1.2 +/- 0.1 nmol/l, P < 0.01 and P < 0.05, respectively) than in CONT (552 +/- 54 and 1.9 +/- 0.1) rats, but they were not different between CONT and INT rats (648 +/- 150 and 2.0 +/- 0.4). The insulin and C-peptide responses to the rise in plasma glucose from 13 to 22 mmol/l were lower in both INT (1,188 +/- 204 pmol/l and 3.0 +/- 0.3 nmol/l, P < 0.01 and P < 0.001) and OLE (432 +/- 60 and 1.7 +/- 0.2, P < 0.001 vs. CONT or INT) rats than in CONT rats (1,662 +/- 174 and 5.0 +/- 0.6). In summary, 1) both INT and OLE decreased GSIS in vivo in rats, and 2) the impairing effect of INT on GSIS was less than that of OLE, which might be due to the different type of fatty acid (mostly polyunsaturated in INT versus monounsaturated as OLE) and/or to differential effects of INT and OLE on insulin sensitivity. In conclusion, prolonged elevation of plasma FFAs can desensitize the insulin secretory response to glucose in vivo, thus inducing a beta-cell defect that is similar to that found in type 2 diabetes.  (+info)

Effects of fatty acids and ketone bodies on basal insulin secretion in type 2 diabetes. (3/477)

The objective of this study was to assess the role of free fatty acids (FFAs) as insulin secretagogues in patients with type 2 diabetes. To this end, basal insulin secretion rates (ISR) in response to acute increases in plasma FFAs were evaluated in patients with type 2 diabetes and in age- and weight-matched nondiabetic control subjects during 1) intravenous infusion of lipid plus heparin (L/H), which stimulated intravascular lipolysis, and 2) the FFA rebound, which followed lowering of plasma FFAs with nicotinic acid (NA) and was a consequence of increased lipolysis from the subject's own adipose tissue. At comparable euglycemia, diabetic patients had similar ISR but higher plasma beta-hydroxybutyrate (beta-OHB) levels during L/H infusion and higher plasma FFA and beta-OHB levels during the FFA rebound than nondiabetic control subjects. Correlating ISR with plasma FFA plus beta-OHB levels showed that in response to the same changes in FFA plus beta-OHB levels, diabetic patients secreted approximately 30% less insulin than nondiabetic control subjects. In addition, twice as much insulin was secreted during L/H infusion as during the FFA rebound in response to the same FFA/beta-OHB stimulation by both diabetic patients and control subjects. Glycerol, which was present in the infused lipid (272 mmol/l) did not affect ISR. We concluded that 1) assessment of FFA effects on ISR requires consideration of effects on ISR by ketone bodies; 2) ISR responses to FFA/beta-OHB were defective in patients with type 2 diabetes (partial beta-cell lipid blindness), but this defect was compensated by elevated plasma levels of FFAs and ketone bodies; and 3) approximately two times more insulin was released per unit change in plasma FFA plus beta-OHB during L/H infusion than during the FFA rebound after NA. The reason for this remains to be explored.  (+info)

Free fatty acids impair hepatic insulin extraction in vivo. (4/477)

Hyperinsulinemia is a common finding in obesity and results from insulin hypersecretion and impaired hepatic insulin extraction. In vitro studies have shown that free fatty acids (FFAs), which are often elevated in obesity, can impair insulin binding and degradation in isolated rat hepatocytes. To investigate whether FFAs impair hepatic insulin extraction (E(H)) in vivo, either saline (SAL) or 10% Intralipid (0.03 ml x kg(-1) x min(-1)) plus heparin (0.44 U x kg(-1) x min(-1)) (IH) was infused into normal dogs to elevate FFA levels. Insulin was infused intraportally at 18 pmol x kg(-1) x min(-1) for 150 min (period A, high insulin dose), and then at 2.4 pmol x kg(-1) x min(-1) for another 150 min (period B, low insulin dose). After the low portal insulin dose, additional insulin was infused peripherally at 8.4 pmol x kg(-1) x min(-1) for 120 min (period C) to assess the clearance of insulin from the peripheral plasma. In 16 paired experiments, FFA levels were 1,085 +/- 167, 1,491 +/- 240, 1,159 +/- 221 micromol/l (IH) and 221 +/- 44, 329 +/- 72, 176 +/- 44 micromol/l (SAL) in periods A, B, and C, respectively. Peripheral insulin levels were greater with IH (P < 0.001) than with SAL in all periods (1,620 +/- 114, 126 +/- 12, 1,050 +/- 72 pmol/l for IH vs. 1,344 +/- 168, 96 +/- 4.2, 882 +/- 60 pmol/l for SAL). Glucose clearance was impaired by IH in all periods (P < 0.05), whereas glucose production was slightly increased by IH during period B. Peripheral insulin clearance (Cl) and E(H) were calculated from the insulin infusion rate and insulin concentration data in each period by taking into account the nonlinearity of insulin kinetics. Cl was lower (P < 0.01) with IH (9.6 +/- 0.6, 12.0 +/- 0.9, 10.2 +/- 0.6 ml x kg(-1) x min(-1)) than with SAL (11.2 +/- 1, 13.6 +/- 0.7, 11.9 +/- 0.9 ml x kg(-1) x min(-1)) in periods A, B, and C. E(H) was also lower (P < 0.05) with IH (25 +/- 4, 40 +/- 5, 32 +/- 5%) than with SAL (30 +/- 2.8, 47 +/- 3, 38 +/- 3%). We conclude that FFAs can impair hepatic insulin extraction in vivo at high and low insulin levels, an effect that may contribute to the peripheral hyperinsulinemia of obesity.  (+info)

Evidence for a lipid specific effect in nutrient induced human proximal gastric relaxation. (5/477)

BACKGROUND/AIM: The presence of lipid in the upper gut is able to modify gastrointestinal motor performance, but its influence on the relaxation of the human stomach, which is known to modify gastric emptying, remains incompletely understood. The relaxation of the proximal stomach in response to various lipid concentrations was therefore studied in healthy volunteers. Since the observed effects could be mediated through osmolality or energy sensitive pathways, the effects of equicaloric and equiosmolar non-lipid solutions were also determined. METHODS: The tone of the proximal stomach was measured during stepwise inflation of a non-compliant bag sited in the proximal stomach, both before and after a test meal was delivered intragastrically. Iso-osmolar lipid emulsions were diluted in iso-osmolar saline at concentrations of 1.25, 2.5, 5, 10, and 20%. NaCl solutions at osmolalities of 300, 600, 1200 and 2400 mmol/kg and glucose solutions of 836 and 3344 kJ/l were also given. RESULTS: All lipid meals of 2.5% or greater concentration induced a reduction in gastric tone in a non-dose-dependent manner, responses to 5% lipid (median (range) 74 (62-92)%) being similar to those to 20% lipid (80 (55-83)%; p > 0.05). No relaxation was elicited by isocaloric glucose. NaCl only consistently caused relaxation at 2400 mmol/kg. CONCLUSION: Lipid meals reduce human proximal gastric tone by a lipid specific mechanism, independently of their energy content or osmolality.  (+info)

Amphotericin B in children with malignant disease: a comparison of the toxicities and pharmacokinetics of amphotericin B administered in dextrose versus lipid emulsion. (6/477)

In a prospective, randomized clinical trial, the toxicity of 1 mg of amphotericin B (AmB) per kg of body weight per day infused in 5% dextrose was compared with that of AmB infused in lipid emulsion in children with malignant disease. In an analysis of 82 children who received a full course of 6 days or more of AmB (117 courses), it was shown that there were significant increases in plasma urea and creatinine concentrations and in potassium requirement after 6 days of therapy with both AmB infused in dextrose and AmB infused in lipid emulsion, with there being no difference between the two methods of AmB administration. An intent-to-treat comparison of the numbers of courses affected by acute toxicity (fever, rigors) and chronic toxicity (nephrotoxicity) also indicated that there was no significant difference between AmB infused in dextrose (78 courses) and AmB infused in lipid emulsion (84 courses). The pharmacokinetics of AmB were investigated in 20 children who received AmB in dextrose and 15 children who received AmB in lipid emulsion. Blood samples were collected up to 24 h after administration of the first dose, and the concentration of AmB in plasma was analyzed by a high-performance liquid chromatography assay. The clearance (CL) of AmB in dextrose (0.039 +/- 0.016 liter. h-1. kg-1) was significantly lower (P < 0.005) than the CL of AmB in lipid emulsion (0.062 +/- 0. 024 liter. h-1. kg-1). The steady-state volume of distribution for AmB in dextrose (0.83 +/- 0.33 liter. kg-1) was also significantly lower (P < 0.005) than that for AmB in lipid emulsion (1.47 +/- 0.77 liter. kg-1). Although AmB in lipid emulsion is apparently cleared faster and distributes more widely than AmB in dextrose, this study did not reveal any significant advantage with respect to safety and tolerance in the administration of AmB in lipid emulsion compared to its administration in dextrose in children with malignant disease.  (+info)

Comparison of the toxicity of amphotericin B in 5% dextrose with that of amphotericin B in fat emulsion in a randomized trial with cancer patients. (7/477)

A multicentric randomized trial was undertaken to compare the toxicity of amphotericin B in 5% dextrose with that of amphotericin B in a fat emulsion (Intralipid) in cancer patients. Group 1 (n = 33) received amphotericin B diluted in 5% dextrose with premedication consisting of promethazine plus an antipyretic. Group 2 (n = 28) received amphotericin B diluted in 20% Intralipid without premedication. Amphotericin B was infused daily at a dose of 1 mg/kg of body weight over a 1-h period to members of both groups for empirical antifungal therapy (in neutropenic patients) or for the treatment of documented fungal infections. The majority of patients (80%) received empirical amphotericin B treatment. The two groups were comparable with regard to age, gender, underlying disease, and the following baseline characteristics: use of other nephrotoxic drugs and serum levels of potassium and creatinine. The median cumulative doses of amphotericin B were 240 mg in group 1 and 245 mg in group 2 (P = 0.73). Acute adverse events occurred in 88% of patients in group 1 and in 71% of those in group 2 (P = 0.11). Forty percent of the infusions in group 1 were associated with fever, compared to 23% in group 2 (P < 0.0001). In addition, patients in group 2 required less meperidine for the control of acute adverse events (P = 0.008), and fewer members of this group presented with hypokalemia (P = 0.004) or rigors (P < 0.0001). There was no difference in the proportions of patients with nephrotoxicity (P = 0.44). The success rates of empirical antifungal treatment were similar in the two groups (P = 0.9). Amphotericin B diluted in a lipid emulsion seems to be associated with a smaller number of acute adverse events and fewer cases of hypokalemia than amphotericin B diluted in 5% dextrose.  (+info)

Acute enhancement of insulin secretion by FFA in humans is lost with prolonged FFA elevation. (8/477)

The in vivo effect of elevated free fatty acids (FFA) on beta-cell function in humans remains extremely controversial. We examined, in healthy young men, the acute (90 min) and chronic (48 h) effects of an approximately twofold elevation of plasma FFA vs. control on glucose-stimulated insulin secretion (GSIS). GSIS was studied in response to a graded intravenous glucose infusion (peak plasma glucose, approximately 10 mmol/l, n = 8) and a two-step hyperglycemic clamp (10 and 20 mmol/l, n = 8). In the acute studies, GSIS was significantly higher, insulin sensitivity index (SI) was lower, and disposition index (DI = insulin sensitivity x insulin secretion) was unchanged with elevated FFA vs. control [2-step clamp: DI = 8.9 +/- 1.4 x 10(-3) l2. kg-1. min-2 in control vs. 10.0 +/- 1.9 x 10(-3) l2. kg-1. min-2 with high FFA, P = nonsignificant (NS)]. In the chronic studies, there was no difference in absolute GSIS between control and high FFA studies, but there was a reduction in SI and a loss of the expected compensatory increase in insulin secretion as assessed by the DI (2-step clamp: DI = 10.0 +/- 1.2 x 10(-3) l2. kg-1. min-2 in control vs. 6.1 +/- 0.7 x 10(-3) l2. kg-1. min-2 with high FFA, P = 0.01). In summary, 1) acute and chronic FFA elevation induces insulin resistance; 2) with acute FFA elevation, this insulin resistance is precisely countered by an FFA-induced increase in insulin secretion, such that DI does not change; and 3) chronic FFA elevation disables this beta-cell compensation.  (+info)

Fat emulsions for intravenous use are a type of parenteral nutrition solution that contain fat in the form of triglycerides, which are broken down and absorbed into the body to provide a source of energy and essential fatty acids. These emulsions are typically used in patients who are unable to consume food orally or enterally, such as those with gastrointestinal tract disorders, malabsorption syndromes, or severe injuries.

The fat emulsion is usually combined with other nutrients, such as carbohydrates and amino acids, to create a complete parenteral nutrition solution that meets the patient's nutritional needs. The emulsion is administered through a vein using a sterile technique to prevent infection.

Fat emulsions are typically made from soybean oil or a mixture of soybean and medium-chain triglyceride (MCT) oils. MCTs are more easily absorbed than long-chain triglycerides (LCTs), which are found in soybean oil, and may be used in patients with malabsorption syndromes or other conditions that affect fat absorption.

It is important to monitor patients receiving intravenous fat emulsions for signs of complications such as infection, hyperlipidemia (elevated levels of fats in the blood), and liver function abnormalities.

An emulsion is a type of stable mixture of two immiscible liquids, such as oil and water, which are normally unable to mix together uniformly. In an emulsion, one liquid (the dispersed phase) is broken down into small droplets and distributed throughout the other liquid (the continuous phase), creating a stable, cloudy mixture.

In medical terms, emulsions can be used in various pharmaceutical and cosmetic applications. For example, certain medications may be formulated as oil-in-water or water-in-oil emulsions to improve their absorption, stability, or palatability. Similarly, some skincare products and makeup removers contain emulsifiers that help create stable mixtures of water and oils, allowing for effective cleansing and moisturizing.

Emulsions can also occur naturally in the body, such as in the digestion of fats. The bile salts produced by the liver help to form small droplets of dietary lipids (oil) within the watery environment of the small intestine, allowing for efficient absorption and metabolism of these nutrients.

Emulsifying agents, also known as emulsifiers, are substances that help to mix two immiscible liquids, such as oil and water, to form a stable emulsion. Emulsifiers work by reducing the surface tension between the two liquids, allowing them to mix together and remain mixed. They are often used in food production, cosmetics, and pharmaceuticals to create smooth and consistent products. Examples of emulsifying agents include lecithin, egg yolk, and various synthetic compounds.

Soybean oil is a vegetable oil extracted from the seeds of the soybean (Glycine max). It is one of the most widely consumed cooking oils and is also used in a variety of food and non-food applications.

Medically, soybean oil is sometimes used as a vehicle for administering certain medications, particularly those that are intended to be absorbed through the skin. It is also used as a dietary supplement and has been studied for its potential health benefits, including its ability to lower cholesterol levels and reduce the risk of heart disease.

However, it's important to note that soybean oil is high in omega-6 fatty acids, which can contribute to inflammation when consumed in excess. Therefore, it should be used in moderation as part of a balanced diet.

Parenteral nutrition (PN) is a medical term used to describe the delivery of nutrients directly into a patient's bloodstream through a vein, bypassing the gastrointestinal tract. It is a specialized medical treatment that is typically used when a patient cannot receive adequate nutrition through enteral feeding, which involves the ingestion and digestion of food through the mouth or a feeding tube.

PN can be used to provide essential nutrients such as carbohydrates, proteins, fats, vitamins, minerals, and electrolytes to patients who have conditions that prevent them from absorbing nutrients through their gut, such as severe gastrointestinal tract disorders, malabsorption syndromes, or short bowel syndrome.

PN is administered through a catheter that is inserted into a vein, typically in the chest or arm. The nutrient solution is prepared under sterile conditions and delivered through an infusion pump to ensure accurate and controlled delivery of the solution.

While PN can be a life-saving intervention for some patients, it also carries risks such as infection, inflammation, and organ damage. Therefore, it should only be prescribed and administered by healthcare professionals with specialized training in this area.

Fats, also known as lipids, are a broad group of organic compounds that are insoluble in water but soluble in nonpolar organic solvents. In the body, fats serve as a major fuel source, providing twice the amount of energy per gram compared to carbohydrates and proteins. They also play crucial roles in maintaining cell membrane structure and function, serving as precursors for various signaling molecules, and assisting in the absorption and transport of fat-soluble vitamins.

There are several types of fats:

1. Saturated fats: These fats contain no double bonds between their carbon atoms and are typically solid at room temperature. They are mainly found in animal products, such as meat, dairy, and eggs, as well as in some plant-based sources like coconut oil and palm kernel oil. Consuming high amounts of saturated fats can raise levels of harmful low-density lipoprotein (LDL) cholesterol in the blood, increasing the risk of heart disease.
2. Unsaturated fats: These fats contain one or more double bonds between their carbon atoms and are usually liquid at room temperature. They can be further divided into monounsaturated fats (one double bond) and polyunsaturated fats (two or more double bonds). Unsaturated fats, especially those from plant sources, tend to have beneficial effects on heart health by lowering LDL cholesterol levels and increasing high-density lipoprotein (HDL) cholesterol levels.
3. Trans fats: These are unsaturated fats that have undergone a process called hydrogenation, which adds hydrogen atoms to the double bonds, making them more saturated and solid at room temperature. Partially hydrogenated trans fats are commonly found in processed foods, such as baked goods, fried foods, and snack foods. Consumption of trans fats has been linked to increased risks of heart disease, stroke, and type 2 diabetes.
4. Omega-3 fatty acids: These are a specific type of polyunsaturated fat that is essential for human health. They cannot be synthesized by the body and must be obtained through diet. Omega-3 fatty acids have been shown to have numerous health benefits, including reducing inflammation, improving heart health, and supporting brain function.
5. Omega-6 fatty acids: These are another type of polyunsaturated fat that is essential for human health. They can be synthesized by the body but must also be obtained through diet. While omega-6 fatty acids are necessary for various bodily functions, excessive consumption can contribute to inflammation and other health issues. It is recommended to maintain a balanced ratio of omega-3 to omega-6 fatty acids in the diet.

Total Parenteral Nutrition (TPN) is a medical term used to describe a specialized nutritional support system that is delivered through a vein (intravenously). It provides all the necessary nutrients that a patient needs, such as carbohydrates, proteins, fats, vitamins, and minerals. TPN is typically used when a patient cannot eat or digest food through their gastrointestinal tract for various reasons, such as severe malabsorption, intestinal obstruction, or inflammatory bowel disease. The term "total" indicates that the nutritional support is complete and meets all of the patient's nutritional needs.

Dietary fats, also known as fatty acids, are a major nutrient that the body needs for energy and various functions. They are an essential component of cell membranes and hormones, and they help the body absorb certain vitamins. There are several types of dietary fats:

1. Saturated fats: These are typically solid at room temperature and are found in animal products such as meat, butter, and cheese, as well as tropical oils like coconut and palm oil. Consuming a high amount of saturated fats can raise levels of unhealthy LDL cholesterol and increase the risk of heart disease.
2. Unsaturated fats: These are typically liquid at room temperature and can be further divided into monounsaturated and polyunsaturated fats. Monounsaturated fats, found in foods such as olive oil, avocados, and nuts, can help lower levels of unhealthy LDL cholesterol while maintaining levels of healthy HDL cholesterol. Polyunsaturated fats, found in foods such as fatty fish, flaxseeds, and walnuts, have similar effects on cholesterol levels and also provide essential omega-3 and omega-6 fatty acids that the body cannot produce on its own.
3. Trans fats: These are unsaturated fats that have been chemically modified to be solid at room temperature. They are often found in processed foods such as baked goods, fried foods, and snack foods. Consuming trans fats can raise levels of unhealthy LDL cholesterol and lower levels of healthy HDL cholesterol, increasing the risk of heart disease.

It is recommended to limit intake of saturated and trans fats and to consume more unsaturated fats as part of a healthy diet.

In the context of medicine and pharmacology, oils are typically defined as lipid-based substances that are derived from plants or animals. They are made up of molecules called fatty acids, which can be either saturated or unsaturated. Oils are often used in medical treatments and therapies due to their ability to deliver active ingredients through the skin, as well as their moisturizing and soothing properties. Some oils, such as essential oils, are also used in aromatherapy for their potential therapeutic benefits. However, it's important to note that some oils can be toxic or irritating if ingested or applied to the skin in large amounts, so they should always be used with caution and under the guidance of a healthcare professional.

Medical definitions generally do not include plant oils as a specific term. However, in a biological or biochemical context, plant oils, also known as vegetable oils, are defined as lipid extracts derived from various parts of plants such as seeds, fruits, and leaves. They mainly consist of triglycerides, which are esters of glycerol and three fatty acids. The composition of fatty acids can vary between different plant sources, leading to a range of physical and chemical properties that make plant oils useful for various applications in the pharmaceutical, cosmetic, and food industries. Some common examples of plant oils include olive oil, coconut oil, sunflower oil, and jojoba oil.

Triglycerides are the most common type of fat in the body, and they're found in the food we eat. They're carried in the bloodstream to provide energy to the cells in our body. High levels of triglycerides in the blood can increase the risk of heart disease, especially in combination with other risk factors such as high LDL (bad) cholesterol, low HDL (good) cholesterol, and high blood pressure.

It's important to note that while triglycerides are a type of fat, they should not be confused with cholesterol, which is a waxy substance found in the cells of our body. Both triglycerides and cholesterol are important for maintaining good health, but high levels of either can increase the risk of heart disease.

Triglyceride levels are measured through a blood test called a lipid panel or lipid profile. A normal triglyceride level is less than 150 mg/dL. Borderline-high levels range from 150 to 199 mg/dL, high levels range from 200 to 499 mg/dL, and very high levels are 500 mg/dL or higher.

Elevated triglycerides can be caused by various factors such as obesity, physical inactivity, excessive alcohol consumption, smoking, and certain medical conditions like diabetes, hypothyroidism, and kidney disease. Medications such as beta-blockers, steroids, and diuretics can also raise triglyceride levels.

Lifestyle changes such as losing weight, exercising regularly, eating a healthy diet low in saturated and trans fats, avoiding excessive alcohol consumption, and quitting smoking can help lower triglyceride levels. In some cases, medication may be necessary to reduce triglycerides to recommended levels.

Nonesterified fatty acids (NEFA), also known as free fatty acids (FFA), refer to fatty acid molecules that are not bound to glycerol in the form of triglycerides or other esters. In the bloodstream, NEFAs are transported while bound to albumin and can serve as a source of energy for peripheral tissues. Under normal physiological conditions, NEFA levels are tightly regulated by the body; however, elevated NEFA levels have been associated with various metabolic disorders such as insulin resistance, obesity, and type 2 diabetes.

Cholecystokinin (CCK) is a hormone that is produced in the duodenum (the first part of the small intestine) and in the brain. It is released into the bloodstream in response to food, particularly fatty foods, and plays several roles in the digestive process.

In the digestive system, CCK stimulates the contraction of the gallbladder, which releases bile into the small intestine to help digest fats. It also inhibits the release of acid from the stomach and slows down the movement of food through the intestines.

In the brain, CCK acts as a neurotransmitter and has been shown to have effects on appetite regulation, mood, and memory. It may play a role in the feeling of fullness or satiety after eating, and may also be involved in anxiety and panic disorders.

CCK is sometimes referred to as "gallbladder-stimulating hormone" or "pancreozymin," although these terms are less commonly used than "cholecystokinin."

Parenteral infusions refer to the administration of fluids or medications directly into a patient's vein or subcutaneous tissue using a needle or catheter. This route bypasses the gastrointestinal tract and allows for rapid absorption and onset of action. Parenteral infusions can be used to correct fluid and electrolyte imbalances, administer medications that cannot be given orally, provide nutritional support, and deliver blood products. Common types of parenteral infusions include intravenous (IV) drips, IV push, and subcutaneous infusions. It is important that parenteral infusions are administered using aseptic technique to reduce the risk of infection.

Lipids are a broad group of organic compounds that are insoluble in water but soluble in nonpolar organic solvents. They include fats, waxes, sterols, fat-soluble vitamins (such as vitamins A, D, E, and K), monoglycerides, diglycerides, triglycerides, and phospholipids. Lipids serve many important functions in the body, including energy storage, acting as structural components of cell membranes, and serving as signaling molecules. High levels of certain lipids, particularly cholesterol and triglycerides, in the blood are associated with an increased risk of cardiovascular disease.

Glycerol, also known as glycerine or glycerin, is a simple polyol (a sugar alcohol) with a sweet taste and a thick, syrupy consistency. It is a colorless, odorless, viscous liquid that is slightly soluble in water and freely miscible with ethanol and ether.

In the medical field, glycerol is often used as a medication or supplement. It can be used as a laxative to treat constipation, as a source of calories and energy for people who cannot eat by mouth, and as a way to prevent dehydration in people with certain medical conditions.

Glycerol is also used in the production of various medical products, such as medications, skin care products, and vaccines. It acts as a humectant, which means it helps to keep things moist, and it can also be used as a solvent or preservative.

In addition to its medical uses, glycerol is also widely used in the food industry as a sweetener, thickening agent, and moisture-retaining agent. It is generally recognized as safe (GRAS) by the U.S. Food and Drug Administration (FDA).

Glucose is a simple monosaccharide (or single sugar) that serves as the primary source of energy for living organisms. It's a fundamental molecule in biology, often referred to as "dextrose" or "grape sugar." Glucose has the molecular formula C6H12O6 and is vital to the functioning of cells, especially those in the brain and nervous system.

In the body, glucose is derived from the digestion of carbohydrates in food, and it's transported around the body via the bloodstream to cells where it can be used for energy. Cells convert glucose into a usable form through a process called cellular respiration, which involves a series of metabolic reactions that generate adenosine triphosphate (ATP)—the main currency of energy in cells.

Glucose is also stored in the liver and muscles as glycogen, a polysaccharide (multiple sugar) that can be broken down back into glucose when needed for energy between meals or during physical activity. Maintaining appropriate blood glucose levels is crucial for overall health, and imbalances can lead to conditions such as diabetes mellitus.

Triolein is a type of triglyceride, which is a kind of fat molecule. More specifically, triolein is the triglyceride formed from three molecules of oleic acid, a common monounsaturated fatty acid. It is often used in scientific research and studies involving lipid metabolism, and it can be found in various vegetable oils and animal fats.

A "fat body" is not a medical term that is typically used to describe human anatomy. It is more commonly used in the context of insects and other invertebrates, where it refers to a specialized tissue that functions to store energy in the form of fat.

However, in humans, we do have adipose tissue, which is the medical term for body fat. Adipose tissue is found throughout the body, but is particularly concentrated in certain areas such as the abdomen, hips, and thighs. It serves a variety of functions, including storing energy, insulating the body, and producing hormones that regulate metabolism and appetite.

If you are looking for information on obesity or excess body fat in humans, there are many medical resources available to help you understand these topics better.

A newborn infant is a baby who is within the first 28 days of life. This period is also referred to as the neonatal period. Newborns require specialized care and attention due to their immature bodily systems and increased vulnerability to various health issues. They are closely monitored for signs of well-being, growth, and development during this critical time.

I'm sorry for any confusion, but "Fluorocarbons" are not typically associated with medical definitions. Fluorocarbons are chemical compounds that contain carbon atoms bonded to fluorine atoms. They are often used in a variety of applications including refrigerants, fire extinguishing agents, and in the manufacturing of Teflon and other non-stick coatings.

If you have any medical terms or concepts you'd like me to define or explain, please let me know!

Intra-abdominal fat, also known as visceral fat, is the fat that is stored within the abdominal cavity and surrounds the internal organs such as the liver, pancreas, and intestines. It's different from subcutaneous fat, which is the fat found just under the skin. Intra-abdominal fat is metabolically active and has been linked to an increased risk of various health conditions, including type 2 diabetes, heart disease, high blood pressure, and stroke. The accumulation of intra-abdominal fat can be influenced by factors such as diet, physical activity, genetics, and age. Waist circumference and imaging tests, such as CT scans and MRIs, are commonly used to measure intra-abdominal fat.

Subcutaneous fat, also known as hypodermic fat, is the layer of fat found beneath the skin and above the muscle fascia, which is the fibrous connective tissue covering the muscles. It serves as an energy reserve, insulation to maintain body temperature, and a cushion to protect underlying structures. Subcutaneous fat is distinct from visceral fat, which is found surrounding internal organs in the abdominal cavity.

Body fat distribution refers to the way in which adipose tissue (fat) is distributed throughout the body. There are two main types of body fat distribution: android or central/abdominal distribution and gynoid or peripheral distribution.

Android or central/abdominal distribution is characterized by a higher proportion of fat deposited in the abdominal area, surrounding internal organs (visceral fat) and between muscle fibers (intramuscular fat). This pattern is more common in men and is associated with an increased risk of metabolic diseases such as type 2 diabetes, hypertension, dyslipidemia, and cardiovascular disease.

Gynoid or peripheral distribution is characterized by a higher proportion of fat deposited in the hips, thighs, and buttocks. This pattern is more common in women and is generally considered less harmful to health than android distribution. However, excessive accumulation of body fat, regardless of its distribution, can lead to obesity-related health problems.

It's important to note that body fat distribution can be influenced by various factors, including genetics, hormones, lifestyle, and environmental factors. Assessing body fat distribution is an essential aspect of evaluating overall health and disease risk.

Abdominal fat, also known as visceral fat, is the fat that is stored in the abdominal cavity and surrounds the internal organs such as the liver, pancreas, and intestines. It is different from subcutaneous fat, which is the fat located just under the skin, and is often measured using techniques such as CT scans or MRI to assess health risks. Excess abdominal fat has been linked to an increased risk of various health conditions, including type 2 diabetes, heart disease, and stroke.

Adipose tissue, also known as fatty tissue, is a type of connective tissue that is composed mainly of adipocytes (fat cells). It is found throughout the body, but is particularly abundant in the abdominal cavity, beneath the skin, and around organs such as the heart and kidneys.

Adipose tissue serves several important functions in the body. One of its primary roles is to store energy in the form of fat, which can be mobilized and used as an energy source during periods of fasting or exercise. Adipose tissue also provides insulation and cushioning for the body, and produces hormones that help regulate metabolism, appetite, and reproductive function.

There are two main types of adipose tissue: white adipose tissue (WAT) and brown adipose tissue (BAT). WAT is the more common form and is responsible for storing energy as fat. BAT, on the other hand, contains a higher number of mitochondria and is involved in heat production and energy expenditure.

Excessive accumulation of adipose tissue can lead to obesity, which is associated with an increased risk of various health problems such as diabetes, heart disease, and certain types of cancer.

Polysorbates are a type of nonionic surfactant (a compound that lowers the surface tension between two substances, such as oil and water) commonly used in pharmaceuticals, foods, and cosmetics. They are derived from sorbitol and reacted with ethylene oxide to create a polyoxyethylene structure. The most common types of polysorbates used in medicine are polysorbate 20, polysorbate 40, and polysorbate 60, which differ in the number of oxyethylene groups in their molecular structure.

Polysorbates are often added to pharmaceutical formulations as emulsifiers, solubilizers, or stabilizers. They help to improve the solubility and stability of drugs that are otherwise insoluble in water, allowing for better absorption and bioavailability. Polysorbates can also prevent the aggregation and precipitation of proteins in injectable formulations.

In addition to their use in pharmaceuticals, polysorbates are also used as emulsifiers in food products such as ice cream, salad dressings, and baked goods. They help to mix oil and water-based ingredients together and prevent them from separating. In cosmetics, polysorbates are used as surfactants, solubilizers, and stabilizers in a variety of personal care products.

It is important to note that some people may have allergic reactions to polysorbates, particularly those with sensitivities to sorbitol or other ingredients used in their production. Therefore, it is essential to carefully consider the potential risks and benefits of using products containing polysorbates in individuals who may be at risk for adverse reactions.

Fat embolism is a medical condition that occurs when fat globules enter the bloodstream and block small blood vessels (arterioles and capillaries) in various tissues and organs. This can lead to inflammation, tissue damage, and potentially life-threatening complications.

Fat embolism typically occurs as a result of trauma, such as long bone fractures or orthopedic surgeries, where fat cells from the marrow of the broken bone enter the bloodstream. It can also occur in other conditions that cause fat to be released into the circulation, such as pancreatitis, decompression sickness, and certain medical procedures like liposuction.

Symptoms of fat embolism may include respiratory distress, fever, confusion, petechial rash (small purple or red spots on the skin), and a decrease in oxygen levels. In severe cases, it can lead to acute respiratory distress syndrome (ARDS) and even death. Treatment typically involves supportive care, such as oxygen therapy, mechanical ventilation, and medications to manage symptoms and prevent complications.

In the context of medical and health sciences, particle size generally refers to the diameter or dimension of particles, which can be in the form of solid particles, droplets, or aerosols. These particles may include airborne pollutants, pharmaceutical drugs, or medical devices such as nanoparticles used in drug delivery systems.

Particle size is an important factor to consider in various medical applications because it can affect the behavior and interactions of particles with biological systems. For example, smaller particle sizes can lead to greater absorption and distribution throughout the body, while larger particle sizes may be filtered out by the body's natural defense mechanisms. Therefore, understanding particle size and its implications is crucial for optimizing the safety and efficacy of medical treatments and interventions.

Medical Definition of Mineral Oil:

Mineral oil is a commonly used laxative, which is a substance that promotes bowel movements. It is a non-digestible, odorless, and tasteless oil that is derived from petroleum. When taken orally, mineral oil passes through the digestive system without being absorbed, helping to soften stools and relieve constipation by increasing the weight and size of the stool, stimulating the reflexes in the intestines that trigger bowel movements.

Mineral oil is also used topically as a moisturizer and emollient for dry skin conditions such as eczema and dermatitis. It forms a barrier on the skin, preventing moisture loss and protecting the skin from irritants. However, mineral oil should not be used on broken or inflamed skin, as it can trap bacteria and delay healing.

It is important to note that long-term use of mineral oil laxatives can lead to dependence and may interfere with the absorption of fat-soluble vitamins such as A, D, E, and K. Therefore, it should be used only under the guidance of a healthcare professional.

Pharmaceutical Preparations - Fat Emulsions, Intravenous PubMed MeSh Term *Overview. Overview. subject area of * Pressure- ... Proceedings From FDA/ASPEN Public Workshop: Clinical Trial Design for Intravenous Fat Emulsion Products, October 29, 2013 ...
Fat Emulsion) may treat, side effects, dosage, drug interactions, warnings, patient labeling, reviews, and related medications ... fat emulsion) (A 20% INTRAVENOUS FAT EMULSION) IS A STERILE, NON-PYROGENIC FAT EMULSION PREPARED FOR INTRAVENOUS ADMINISTRATION ... INTRALIPID® 20% (20% i.v. fat emulsion) (A 20% INTRAVENOUSA FAT EMULSION) HAS AN OSMOLALITY OF APPROXIMATELY 350 MOSMOL/KG ... Fat overload syndrome is a rare condition that has been reported with intravenous lipid injectable emulsions and is ...
Lipid emulsion or fat emulsion refers to an emulsion of fat for human intravenous use, to administer nutrients to critically- ... Hallberg D, Holm I, Obel AL, Schuberth O, Wretlind A (April 1967). "Fat emulsions for complete intravenous nutrition". ... The possibility of lipid emulsions as an alternative drug delivery medium is under works. Intravenous lipid emulsions have been ... The emulsion is used as a component of intravenous nutrition for people who are unable to get nutrition via an oral diet. These ...
Fat Emulsions, Intravenous / administration & dosage * Fat Emulsions, Intravenous / metabolism * Female * Humans * Male ...
Generic name: i.v. fat emulsion. Dosage form: intravenous emulsion. Drug class: Intravenous nutritional products ... Fat overload syndrome is a rare condition that has been reported with intravenous lipid injectable emulsions and is ... Inform patients and caregivers that fat overload syndrome has been reported with the use of intravenous lipid emulsions. If ... 5.1 Clinical Decompensation with Rapid Infusion of Intravenous Lipid Emulsions in Neonates and Infants. In the postmarketing ...
Hemodynamic effects of intravenous fat emulsion in an animal model of severe verapamil toxicity resuscitated with atropine, ... BACKGROUND: Intravenous fat emulsion (IFE) decreases cardiotoxicity from several lipid-soluble drugs, including verapamil.. ...
Do not add INFUVITE PEDIATRIC directly to intravenous fat emulsions.. *Consult appropriate references for additional listings ... Dosage form: intravenous infusion. Drug class: Vitamin and mineral combinations. Medically reviewed by Drugs.com. Last updated ... for intravenous use intended for administration by intravenous infusion after dilution:. *INFUVITE PEDIATRIC Single Dose ... A weight-based volume from each vial must be added directly to dextrose or saline solution prior to intravenous administration ...
A life-threatening flecainide overdose treated with intravenous fat emulsion. Pacing Clin Electrophysiol. 2013 Mar. 36(3):e87-9 ... Severe propranolol and ethanol overdose with wide complex tachycardia treated with intravenous lipid emulsion: a case report. ... Diltiazem poisoning treated with hyperinsulinemic euglycemia therapy and intravenous lipid emulsion. Eur J Emerg Med. 2011 Apr ... Dosages: Intravenous, 150 mg over 10 minutes followed by 1 mg/min for 6 hours and 0.5 mg/min for the remaining time; oral, ...
"Fat Chance of Survival: Intravenous Lipid Emulsion for Oral Cardiovascular Toxicant Poisoning". Bruce K. Fehr Memorial Lecture ... Corwin DJ, Topjian A, Banwell BL, Osterhoudt K. Adverse events associated with a largedose of lipid emulsion for suspected ... Dela Cruz M, Bodenstab H, Vearrier D, Osterhoudt K. Review of recommendations for use of intravenous sodium bicarbonate to ...
The effect of fat emulsion (Intralipid) on essential fatty acid deficiency in infants receiving intravenous alimentation. J. ... Institute of Medicine (US). Dietary Fat: Total Fat and Fatty Acids. In Dietary References Intakes: The Essential Guide to ... Burr, G.O.; Burr, M.M. A new deficiency disease produced by the rigid exclusion of fat from the diet. J. Biol. Chem. 1929, 82, ... Wesson, L.G.; Burr, G.O. The metabolic rate and respiratory quotients of rats on a fat-deficient diet. J. Biol. Chem. 1931, 91 ...
Hemodynamic effects of intravenous fat emulsion in an animal model of severe verapamil toxicity resuscitated with atropine, ... Sebe A, Dişel NR, Açıkalın Akpınar A, Karakoç E. Role of intravenous lipid emulsions in the management of calcium channel ... Systematic review of clinical adverse events reported after acute intravenous lipid emulsion administration. Clin Toxicol ( ... Successful treatment of metoprolol-induced cardiac arrest with high-dose insulin, lipid emulsion, and ECMO. Am J Emerg Med. ...
Parenteral nutrition; fat emulsions for intravenous nutrition in man. J Lab Clin Med. 1949;34:699-712. ... Electrolytes can destabilise fat emulsions by neutralising the negative charge on the emulsion surface, causing precipitate and ... A principal energy source in parenteral nutrition formulations can come from a combined fat and protein emulsion that is ... Overall proportion of intravenous energy and protein required by a patient is determined by a variety of criteria, including ...
We conclude that a soybean oil emulsion increased select brain inflammatory cytokines and multicomponent lipid emulsions ... fats, vitamins and minerals. Fats are especially important to preterm infants because they need key fatty acids to support ... Interpretive Summary: Many infants born prematurely in the United States each year rely on intravenous nutrition support for ... or TPN with one of three parenteral lipid emulsions: Intralipid (IL), SMOFlipid (SMOF) or an experimental emulsion (EXP). ...
Biber B, Johannesson G, Lennander O, Martner J, Sonander H, Werner O: Intravenous infusion of halothane dissolved in fat: ... THE ED50and LD50of intravenous isoflurane lipid emulsion (ILE) in mice,1the anesthetic and physiologic effects of intravenous ... Comparison of Minimum Alveolar Concentration between Intravenous Isoflurane Lipid Emulsion and Inhaled Isoflurane in Dogs Xiao- ... Biber B, Johannesson G, Lennander O, Martner J, Sonander H, Werner O: Intravenous infusion of halothane dissolved in fat: ...
3) Intravenous lipid infusion (Vitalipid, an emulsion of fat-soluble vitamins) was reported to be effective in treating a rare ...
Compatibility of Intravenous Fat Emulsion with Antibiotics for Secondary Piggyback Infusion.. Ann Nutr Metab 2018 ; 73: 227-233 ... Visual compatibility of intravenous famotidine with selected drugs.. Am J Hosp Pharm 1989 ; 46: 125-126.. ... Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection.. Am J Hosp ... Ofloxacin intravenous. Compatibility with other antibacterial agents.. Pharm Weekbl [Sci] 1991 ; 13: 207-209.. ...
Hospira expanded a March 2010 recall of its Propofol Injectable Emulsion 1% and Liposyn (Intravenous Fat Emulsion) products ... for a vial defect involving three lots of Propofol Injectable Emulsion in which visible particles embedded in the glass were ...
In cases of serious deficiency, treatment with intravenous Intralipid® (a 10% intravenous fat emulsion made from soybean oil ... as are those who are fed intravenously for long periods with limited or no intravenous fat emulsion. ... A person with a condition that results in fat malabsorption, such as having had a bowel resection, is at higher risk of an EFA ... Essential Fatty Acids (EFAs) are important for optimal health and deemed essential because, unlike other fats, the human body ...
Intravenous glucose, aminoacids, and fat in the postoperative period. A controlled evaluation of each substrate. Craig, R.P., ... and soyabean emulsion were comapred with those of fasting in 4 groups of male patients (closely matched for age, weight, and ... CCR2 modulates inflammatory and metabolic effects of high-fat feeding. Weisberg, S.P., Hunter, D., Huber, R., Lemieux, J., ... CCR2 modulates inflammatory and metabolic effects of high-fat feeding [36].. *Preliminary results indicate that WRN functions ...
Parenteral nutrition intravenous fat emulsions product shortage considerations. Nutr Clin Pract. 2013 Aug; 28(4):528-9. ... Commercial lipid emulsions and all-in-one mixtures for intravenous infusion - composition and physicochemical properties. World ... The Impact of Novel Intravenous Lipid Emulsions. JPEN J Parenter Enteral Nutr. 2015 Sep; 39(1 Suppl):61S-6S. ... Regarding "A Comparison of Fish Oil Sources for Parenteral Lipid Emulsions in a Murine Model". JPEN J Parenter Enteral Nutr. ...
Intravenous lipid emulsions in the prevention and treatment of liver disease in intestinal failure. Rochling, F. A., Mar 2021, ... Intravenous Fat Emulsions 100% * liver diseases 83% * emulsions 58% * Liver Diseases 53% ...
Intravenous Fat Emulsion Does Not Significantly Alter Clotting Markers in Dabigatran-Treated Blood. Stellpflug, S. J., Bond, M ...
Drug - Intralipid, 20% Intravenous Emulsion Fatty Acid Infusion, either in low-dose (30 ml/hr) or medium-dose (60 ml/hr) ... Low Dose Fat-Induced Insulin Resistance. participant.ui.study.eligibility-modal.buttons.check-eligibility ... A Dose Finding Study for Fat-Induced Insulin Resistance in Healthy Volunteers ... due to possible reactions with fat infusate) - For female participants: Positive pregnancy test, presently breast-feeding, or ...
NIRPID INTRAVENOUS FAT EMULSION. Submit a Comment Cancel reply. Your email address will not be published. Required fields are ...
Continuous with intravenous fat emulsion. Every 24 hours. Continuous without intravenous fat emulsion ...
Efficiency of intravenous therapy with Intralipid fat emulsion in patients with early reproductive loss. ...
Factors affecting particle size of an intravenous fat emulsions (2010) Journal Article ...

No FAQ available that match "fat emulsions intravenous"

No images available that match "fat emulsions intravenous"